Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabiximols crossover trial for multiple sclerosis spasticity
2020-003271-18Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in multiple sclerosis (MS) and Muscle spasm (2 arms), sponsored by GW Pharmaceuticals. Primary endpoint: Change in Lower Limb Muscle Tone-6. Started Apr 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on 2020-003271-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003271-18.